Abstract Introduction TRV027, a 'biased'ligand of the angiotensin II type 1 receptor (AT1R),
did not affect a composite clinical outcome at 30 days in a phase 2b acute heart failure …

Aims Currently, no acute heart failure (AHF) therapy definitively improves outcomes.
Reducing morbidity and mortality from acute heart failure (AHF) remains an unmet need …

Abstract The BLAST-AHF (Biased Ligand of the Angiotensin Receptor Study in Acute Heart
Failure) study is designed to test the efficacy and safety of TRV027, a novel biased ligand of …

Background TRVO27 is a β-arrestin biased ligand at the angiotensin 2 type 1 receptor
(AT1R); it antagonizes G-protein coupling while stimulating β-arrestin-mediated signaling …

TRV027 is a novel β‐arrestin biased peptide ligand of the angiotensin II type 1 receptor
(AT1R). The compound antagonizes G protein coupling while simultaneously stimulating β …

Aims A high‐intensity care (HIC) strategy with rapid guideline‐directed medical therapy
(GDMT) up‐titration and close follow‐up visits improved outcomes, compared to usual care …

BACKGROUND: Systolic blood pressure (SBP) is related to the pathophysiologic
development and progression of heart failure (HF) and is inversely associated with adverse …

Aims Changes in systolic blood pressure (SBP) during an admission for acute heart failure
(AHF), especially those leading to hypotension, have been suggested to increase the risk for …

Objective Although vasodilators are used in acute heart failure (AHF) management, there
have been no clear supportive evidence regarding their routine use. Recent European …

Background Compared to heart failure patients with higher systolic blood pressure (SBP),
those with lower SBP have a worse prognosis. To make matters worse, the latter patients …